262 related articles for article (PubMed ID: 12738772)
21. A spoonful of L-fucose-an efficient therapy for GFUS-CDG, a new glycosylation disorder.
Feichtinger RG; Hüllen A; Koller A; Kotzot D; Grote V; Rapp E; Hofbauer P; Brugger K; Thiel C; Mayr JA; Wortmann SB
EMBO Mol Med; 2021 Sep; 13(9):e14332. PubMed ID: 34468083
[TBL] [Abstract][Full Text] [Related]
22. Slc35c2 promotes Notch1 fucosylation and is required for optimal Notch signaling in mammalian cells.
Lu L; Hou X; Shi S; Körner C; Stanley P
J Biol Chem; 2010 Nov; 285(46):36245-54. PubMed ID: 20837470
[TBL] [Abstract][Full Text] [Related]
23. Golgi nucleotide sugar transport and leukocyte adhesion deficiency II.
Hirschberg CB
J Clin Invest; 2001 Jul; 108(1):3-6. PubMed ID: 11435449
[No Abstract] [Full Text] [Related]
24. Biological function of fucosylation in cancer biology.
Miyoshi E; Moriwaki K; Nakagawa T
J Biochem; 2008 Jun; 143(6):725-9. PubMed ID: 18218651
[TBL] [Abstract][Full Text] [Related]
25. Protein O-fucosylation: structure and function.
Holdener BC; Haltiwanger RS
Curr Opin Struct Biol; 2019 Jun; 56():78-86. PubMed ID: 30690220
[TBL] [Abstract][Full Text] [Related]
26. Leukocyte adhesion deficiency II patients with a dual defect of the GDP-fucose transporter.
Helmus Y; Denecke J; Yakubenia S; Robinson P; Lühn K; Watson DL; McGrogan PJ; Vestweber D; Marquardt T; Wild MK
Blood; 2006 May; 107(10):3959-66. PubMed ID: 16455955
[TBL] [Abstract][Full Text] [Related]
27. Correction of leukocyte adhesion deficiency type II with oral fucose.
Marquardt T; Lühn K; Srikrishna G; Freeze HH; Harms E; Vestweber D
Blood; 1999 Dec; 94(12):3976-85. PubMed ID: 10590041
[TBL] [Abstract][Full Text] [Related]
28. Appropriate aglycone modification significantly expands the glycan substrate acceptability of α1,6-fucosyltransferase (FUT8).
Zhang R; Yang Q; Boruah BM; Zong G; Li C; Chapla D; Yang JY; Moremen KW; Wang LX
Biochem J; 2021 Apr; 478(8):1571-1583. PubMed ID: 33734311
[TBL] [Abstract][Full Text] [Related]
29. Defining the mild variant of leukocyte adhesion deficiency type II (SLC35C1-congenital disorder of glycosylation) and response to l-fucose therapy: Insights from two new families and review of the literature.
Tahata S; Raymond K; Quade M; Barnes S; Boyer S; League S; Kumanovics A; Abraham R; Jacob E; Menon P; Morava E
Am J Med Genet A; 2022 Jul; 188(7):2005-2018. PubMed ID: 35338746
[TBL] [Abstract][Full Text] [Related]
30. Decreased availability of GDP-L-fucose in a patient with LAD II with normal GDP-D-mannose dehydratase and FX protein activities.
Körner C; Linnebank M; Koch HG; Harms E; von Figura K; Marquardt T
J Leukoc Biol; 1999 Jul; 66(1):95-8. PubMed ID: 10410995
[TBL] [Abstract][Full Text] [Related]
31. Congenital disorders involving defective N-glycosylation of proteins.
Schachter H
Cell Mol Life Sci; 2001 Jul; 58(8):1085-104. PubMed ID: 11529501
[TBL] [Abstract][Full Text] [Related]
32. Characterization of the specificities of human blood group H gene-specified alpha 1,2-L-fucosyltransferase toward sulfated/sialylated/fucosylated acceptors: evidence for an inverse relationship between alpha 1,2-L-fucosylation of Gal and alpha 1,6-L-fucosylation of asparagine-linked GlcNAc.
Chandrasekaran EV; Jain RK; Larsen RD; Wlasichuk K; Matta KL
Biochemistry; 1996 Jul; 35(27):8914-24. PubMed ID: 8688427
[TBL] [Abstract][Full Text] [Related]
33. Substrate Preference and Interplay of Fucosyltransferase 8 and N-Acetylglucosaminyltransferases.
Tseng TH; Lin TW; Chen CY; Chen CH; Lin JL; Hsu TL; Wong CH
J Am Chem Soc; 2017 Jul; 139(28):9431-9434. PubMed ID: 28678517
[TBL] [Abstract][Full Text] [Related]
34. Increased alpha3-fucosylation of alpha(1)-acid glycoprotein in patients with congenital disorder of glycosylation type IA (CDG-Ia).
Van Dijk W; Koeleman C; Van het Hof B; Poland D; Jakobs C; Jaeken J
FEBS Lett; 2001 Apr; 494(3):232-5. PubMed ID: 11311246
[TBL] [Abstract][Full Text] [Related]
35. Fucosylation in cancer biology and its clinical applications.
Shan M; Yang D; Dou H; Zhang L
Prog Mol Biol Transl Sci; 2019; 162():93-119. PubMed ID: 30905466
[TBL] [Abstract][Full Text] [Related]
36. Expression of genes that control core fucosylation in hepatocellular carcinoma: Systematic review.
Norton PA; Mehta AS
World J Gastroenterol; 2019 Jun; 25(23):2947-2960. PubMed ID: 31249452
[TBL] [Abstract][Full Text] [Related]
37. Leukocyte adhesion deficiency (LAD) type II/carbohydrate deficient glycoprotein (CDG) IIc founder effect and genotype/phenotype correlation.
Etzioni A; Sturla L; Antonellis A; Green ED; Gershoni-Baruch R; Berninsone PM; Hirschberg CB; Tonetti M
Am J Med Genet; 2002 Jun; 110(2):131-5. PubMed ID: 12116250
[TBL] [Abstract][Full Text] [Related]
38. Identification and molecular cloning of a functional GDP-fucose transporter in Drosophila melanogaster.
Lühn K; Laskowska A; Pielage J; Klämbt C; Ipe U; Vestweber D; Wild MK
Exp Cell Res; 2004 Dec; 301(2):242-50. PubMed ID: 15530860
[TBL] [Abstract][Full Text] [Related]
39. Fucose in N-glycans: from plant to man.
Staudacher E; Altmann F; Wilson IB; März L
Biochim Biophys Acta; 1999 Dec; 1473(1):216-36. PubMed ID: 10580141
[TBL] [Abstract][Full Text] [Related]
40. Development of orally active inhibitors of protein and cellular fucosylation.
Okeley NM; Alley SC; Anderson ME; Boursalian TE; Burke PJ; Emmerton KM; Jeffrey SC; Klussman K; Law CL; Sussman D; Toki BE; Westendorf L; Zeng W; Zhang X; Benjamin DR; Senter PD
Proc Natl Acad Sci U S A; 2013 Apr; 110(14):5404-9. PubMed ID: 23493549
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
